Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 3, 2015, Pages 869-874

  Tyagi, Sandeep ^a   Ammerman, Nicole C ^a,b   Li, Si Yang ^a   Adamson, John ^b   Converse, Paul J ^a   Swanson, Rosemary V ^b,c   Almeida, Deepak V ^a,b   Grosset, Jacques H ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Clofazimine; Experimental chemotherapy; Mouse model; Tuberculosis; Tuberculosis treatment

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TISSUE LEVEL; FEMALE; LIMIT OF DETECTION; LUNG; LUNG LESION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SPLEEN; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; TUBERCULOSIS;

MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED BALB C; TUBERCULOSIS;

EID: 84921395723     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416951112     Document Type: Article

References (26)

1. Barry VC, Conalty ML, Gaffney EE (1956) Antituberculosis activity in the phenazine series; Isomeric pigments obtained by oxidation of o-phenylenediamine derivatives. J Pharm Pharmacol 8(12):1089-1096.
2. Barry VC, et al. (1957) A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179(4568):1013-1015.
3. Barry VC (1969) Synthetic phenazine derivatives and mycobacterial disease: A twenty year investigation. Boyle Medal Lecture no. 16. Sci Proc R Dublin Soc Ser A 3:153-170.
4. World Health Organization (2004) Multidrug Therapy Against Leprosy: Development and Implementation Over the Past 25 Years (WHO Press, Geneva).
5. Van Deun A, et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182(5): 684-692.
6. World Health Organization (2013) Multidrug-Resistant Tuberculosis (MDR-TB). 2013 Update (WHO Press, Geneva).
7. Grosset JH, et al. (2013) Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188(5):608-612.
8. World Health Organization (2013) Global Tuberculosis Report 2013 (WHO Press, Geneva).
9. Rosenthal IM, et al. (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56(8):4331-4340.
10. Yano T, et al. (2011) Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286(12):10276-10287.
11. Andries K, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis . Science 307(5707):223-227.
12. Rustomjee R, et al. (2008) Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 52(8):2831-2835.
13. Banerjee DK, Ellard GA, Gammon PT, Waters MF (1974) Some observations on the pharmacology of clofazimine (B663). Am J Trop Med Hyg 23(6):1110-1115.
14. Levy L (1974) Pharmacologic studies of clofazimine. Am J Trop Med Hyg 23(6): 1097-1109.
15. Mansfield RE (1974) Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 23(6):1116-1119.
16. Baik J, Rosania GR (2012) Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS ONE 7(10):e47494.
17. Baik J, Stringer KA, Mane G, Rosania GR (2013) Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response. Antimicrob Agents Chemother 57(3):1218-1230.
18. Irwin SM, et al. (2014) Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 58(7):4026-4034.
19. Driver ER, et al. (2012) Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56(6):3181-3195.
20. McDougall AC (1974) Electron microscope studies of the antileprosy drug B663 (clofazimine; Lamprene). Int J Lepr Other Mycobact Dis 42(1):1-12.
21. Conalty ML, Barry VC, Jina A (1971) The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system. Int J Lepr Other Mycobact Dis 39(2):479-492.
22. Harper J, et al. (2012) Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205(4):595-602.
23. Zhang M, et al. (2011) Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 183(9):1254-1261.
24. Sloan DJ, et al. (2012) Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol 50(7): 2315-2320.
25. Grosset J, et al. (2012) Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci USA 109(37):15001-15005.
26. Rosenthal IM, et al. (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4(12):e344.